First Wave BioPharma, Inc. (FWBI)

NASDAQ: FWBI · IEX Real-Time Price · USD
0.155
-0.005 (-3.06%)
At close: Aug 17, 2022 3:57 PM
0.161
+0.005 (3.482%)
After-hours: Aug 17, 2022 5:26 PM EDT
-3.06%
Market Cap 6.45M
Revenue (ttm) n/a
Net Income (ttm) -57.67M
Shares Out 41.59M
EPS (ttm) -5.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 682,656
Open 0.162
Previous Close 0.160
Day's Range 0.155 - 0.164
52-Week Range 0.135 - 8.570
Beta 1.74
Analysts Buy
Price Target 9.18 (+5,818.8%)
Earnings Date Aug 15, 2022

About FWBI

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute r... [Read more...]

Industry Biotechnology
IPO Date Oct 11, 2016
CEO James Sapirstein
Employees 17
Stock Exchange NASDAQ
Ticker Symbol FWBI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for FWBI stock is "Buy." The 12-month stock price forecast is 9.18, which is an increase of 5,818.76% from the latest price.

Price Target
$9.18
(5,818.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

First Wave BioPharma, Inc. Announces Private Placement

BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the dev...

Why First Wave BioPharma Shares Are Tanking Today

First Wave BioPharma Inc (NASDAQ: FWBI) shares are plummeting after the company reported topline data from Phase 2 RESERVOIR trial of FW-COV, oral formulation of niclosamide, for COVID-19-related GI inf...

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

BOCA RATON, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the ...

First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product ...

Committee members include globally renowned experts in gastrointestinal diseases, including ulcerative colitis and Crohn's disease Committee members include globally renowned experts in gastrointestinal...

First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

BOCA RATON, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the ...

First Wave BioPharma to Participate in Maxim's 2022 Virtual Growth Conference

BOCA RATON, Fla., March 22, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...

First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference

Poster presentation to feature research involving niclosamide as a potential treatment for mild-to-moderate ulcerative proctitis and ulcerative proctosigmoiditis Poster presentation to feature research ...

First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced At-The-Market Under Nasd...

BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, no...

First Wave BioPharma, Inc. Announces $9 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

BOCA RATON, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non...

First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference

BOCA RATON, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the d...

First Wave BioPharma Files Two Provisional US Patent Applications For Adrulipase

First Wave BioPharma Inc (NASDAQ: FWBI) has filed two new provisional patent applications on adrulipase with the U.S. Patent and Trademark Office (USPTO).  The first application is directed to new lipas...

First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program

BOCA RATON, Fla., Jan. 13, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the d...

First Wave BioPharma Announces Further Adjournment of Annual Meeting

BOCA RATON, Fla., Jan. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the d...

First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related...

No Drug-Related SAEs Reported; Topline Data Expected 1H 2022

First Wave BioPharma to Participate in Two Investor Conferences in January 2022

CEO James Sapirstein to Moderate Panel Discussion during Longwood Healthcare Leaders Conference and Host Virtual Presentation at H.C. Wainwright BioConnect 2022 CEO James Sapirstein to Moderate Panel Di...

First Wave BioPharma Announces Adjournment of Annual Meeting

BOCA RATON, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the d...

First Wave BioPharma Names Brian Feagan, M.D., to Scientific Advisory Board

Appointment of world-renowned gastroenterologist and researcher reflects expanded clinical development of niclosamide in the treatment of inflammatory bowel diseases (IBDs) Appointment of world-renowned...

First Wave BioPharma's CEO and President, James Sapirstein, to Participate in CEO Panel Discussion at 2021 BioFlorida...

Industry leaders to discuss the trends fueling the future of Florida's life sciences industry Industry leaders to discuss the trends fueling the future of Florida's life sciences industry

First Wave BioPharma Stock Jumps On Niclosamide's Favorable Safety Profile In COVID-19 Related GI Infections

The independent data monitoring committee (DMC) has recommended First Wave BioPharma Inc (NASDAQ: FWBI) to continue enrollment in Part 2 of the RESERVOIR Phase 2 trial evaluating FW-COV for COVID-19-rel...

First Wave BioPharma stock rockets after upbeat news on treatment for COVID-19-related GI infections

Shares of First Wave BioPharma Inc. FWBI, -2.58% rocketed 46.6% on very heavy volume in premarket trading Tuesday, after the biopharmaceutical company said an independent data monitoring committee (DMC)...

First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for ...

Review of Data from Initial 25 Patients Completed with Favorable Recommendation Review of Data from Initial 25 Patients Completed with Favorable Recommendation

First Wave Restructures Merger Consideration Payment Terms

First Wave BioPharma Inc (NASDAQ: FWBI) has agreed with the former shareholders of First Wave Bio Inc to amend the payment structure of the initial merger consideration and extend payments into 2023. Re...

First Wave BioPharma Forms Steering Committee for Phase 2a PASSPORT Clinical Trial to Evaluate FW-ICI-AC in Cancer Pa...

Committee members include globally renowned experts in medical oncology, immune checkpoint inhibitor therapeutics, gastrointestinal (GI) diseases and cancer immunotherapy-related GI complications Commit...

First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment...

BOCA RATON, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the d...

First Wave BioPharma Announces Two Additions to Scientific Advisory Board

Globally Recognized Experts in Gastrointestinal Diseases, Cystic Fibrosis and Virology to Support Company in Advancing Niclosamide and Adrulipase Clinical Programs Globally Recognized Experts in Gastroi...